

6th International Congress and Exhibition on Endocrine and Diabetic Complications

Global market and analysis:

Worldwide yearly diabetes-related wellbeing consumption is required to add up to US\$678Billions, which is assessed to achieve US\$800.8Billions. At present, 12% of today's human services use can be identified with the treatment of individuals with diabetes, and 34% of today's worldwide spending on diabetes can be tended to by diabetes application administrations and items.

Diabetes therapies hold some of the strongest prospects for pharmaceutical companies. Orally administered anti-diabetic drugs were leading category of drugs in 2014 and showed a rate of growth of at around 6.3% from the total global sales. The total sales for insulin products also increased.

The anti-diabetic products include glucose meters, lancets, test strips, continuous blood glucose meters, insulin, insulin pumps, syringes and other insulin delivery devices and anti-diabetes drugs. The product revenue in bulk comes from the-test strips, insulin and anti-diabetic drugs – which will remain the largest sources of product revenues over the next tenyears.


Anti-diabetic drugs

Global industry, Market, R&D and sales forecasts 2016-2026:

- Anti-diabetic drug revenues to 2026 at overall world level, for 9 therapeutic submarkets and 31 products – assess outlooks for production, marketing and sales.
- Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia – investigate developed and developing countries for demand and revenue potentials.
- Prospects for established competitors, rising companies and new entrants – explore portfolios, opinions, results, strategies, technologies and outlooks for success.
- Review of R&D pipelines – examine progress in research and development, finding technological and medical prospects.
- Analysis of what stimulates and restrains that industry and market – gauge challenges and strengths, helping you compete, gain advantages and succeed.

Top Companies for Diabetes research:

- Eli Lilly
- Novo Nordisk
- Merck & Co
- Sanofi
- Takeda
- AstraZeneca
- Johnson & Johnson



- Novartis
- Becton, Dickson and Company
- Business and Economics of Diabetes

The many medical and engineering dimensions to diabetes technology are matched by an equal number of business, economic, insurance coverage and reimbursement problems that must be solved in order for devices manufacturers to develop and provide these technologies for people with diabetes. Good decisions are necessary to develop diabetes technology, but good business decisions are also necessary for this process to succeed.

Top Universities under Diabetic Research:

Following are the Top Universities which are dealing with Diabetic Research

- Harvard University (Cambridge, MA, USA),
- Massachusetts Institute of Technology (MIT),
- Columbia University (New York, NY, USA)
- Oxford University (Oxford, UK)
- Yale University (New Haven, CT, USA)
- McMaster University (Hamilton, ON, Canada)
- University of Basel (Basel, Switzerland)
- University of Strasbourg (Strasbourg, France)
- University of Bonn (Bonn, Germany)
- KU Leuven (Catholic University of Louvain)
- Swiss Federal Institute of Technology in Lausanne (Lausanne, Switzerland)
- University of California at Santa Barbara (Santa Barbara, CA, USA)
- Free University of Amsterdam (VU Amsterdam).
- Texas A&M University
- Top Hospitals researching on Diabetes

Following are the Top Hospitals and Research Clinic

which are dealing with Diabetic Research:

- Mayo clinic (Rochester, MN),
- Massachusetts General Hospital (Boston, MA)
- Cleveland Clinic (Cleveland, OH)
- Johns Hopkins Hospital (Baltimore, MD)
- USCF Medical Centre (San Francisco, CA)
- Bassetlaw Hospital – Workshop,
Nottinghamshire (UK)
- Addenbrooke’s Hospital – Cambridge, Barnet
General Hospital (UK)
- Cygnet Hospital Beck ton (UK)
- Wooridul Spine Hospital-Seoul (South Korea)
- Fortis Memorial Research Institute (India)
- Gleneagles Medical Centre (Tanglin, Singapore)

For further queries attain us on:

Blake Smith

Program Manager

Diabetes 2020

Email id: endocrinecongress@meetingsnexpo.com